Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5
Open Access
- 1 December 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (23), 13207-13215
- https://doi.org/10.1128/jvi.78.23.13207-13215.2004
Abstract
A novel plasmid-based adenovirus vector system that enables manufacturing of replication-incompetent (ΔE1) adenovirus type 11 (Ad11)-based vectors is described. Ad11 vectors are produced on PER.C6/55K cells yielding high-titer vector batches after purification. Ad11 seroprevalence proves to be significantly lower than that of Ad5, and neutralizing antibody titers against Ad11 are low. Ad11 seroprevalence among human immunodeficiency virus-positive (HIV + ) individuals is as low as that among HIV − individuals, independent of the level of immune suppression. The low level of coinciding seroprevalence between Ad11 and Ad35 in addition to a lack of correlation between high neutralizing antibody titers towards either adenovirus strongly suggest that the limited humoral cross-reactive immunity between these two highly related B viruses appears not to preclude the use of both vectors in the same individual. Ad11 transduces primary cells including smooth muscle cells, synoviocytes, and dendritic cells and cardiovascular tissues with higher efficiency than Ad5. Ad11 and Ad35 appear to have a similar tropism as judged by green fluorescent protein expression levels determined by using a panel of cancer cell lines. In addition, Ad5 preimmunization did not significantly affect Ad11-mediated transduction in C57BL/6 mice. We therefore conclude that the Ad11-based vector represents a novel and useful candidate gene transfer vehicle for vaccination and gene therapy.Keywords
This publication has 42 references indexed in Scilit:
- Neutralizing Antibodies and CD8 + T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine VectorsJournal of Virology, 2004
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003
- Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 VaccinesJournal of Virology, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003
- Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus ImmunityJournal of Virology, 2003
- Improved Adenovirus Vectors for Infection of Cardiovascular TissuesJournal of Virology, 2001
- The Interactions of Peptides with the Innate Immune System Studied with Use of T7 Phage Peptide DisplayMolecular Therapy, 2000
- β-Galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and AdenovirusesHuman Gene Therapy, 1998
- Binding of Human Urokinase-Type Plasminogen Activator to Its ReceptorArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Membrane Cofactor Protein (MCP or CD46): Newest Member of the Regulators of Complement Activation Gene ClusterAnnual Review of Immunology, 1991